129 related articles for article (PubMed ID: 22906260)
1. High serum levels of follistatin in patients with ovarian cancer.
Ren P; Chen FF; Liu HY; Cui XL; Sun Y; Guan JL; Liu ZH; Liu JG; Wang YN
J Int Med Res; 2012; 40(3):877-86. PubMed ID: 22906260
[TBL] [Abstract][Full Text] [Related]
2. Follistatin is a novel biomarker for lung adenocarcinoma in humans.
Chen F; Ren P; Feng Y; Liu H; Sun Y; Liu Z; Ge J; Cui X
PLoS One; 2014; 9(10):e111398. PubMed ID: 25347573
[TBL] [Abstract][Full Text] [Related]
3. High serum follistatin levels in women with ovarian endometriosis.
Florio P; Reis FM; Torres PB; Calonaci F; Abrao MS; Nascimento LL; Franchini M; Cianferoni L; Petraglia F
Hum Reprod; 2009 Oct; 24(10):2600-6. PubMed ID: 19549703
[TBL] [Abstract][Full Text] [Related]
4. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum follistatin levels in the diagnosis of ovarian endometrioma and benign ovarian cysts.
Ant Ö; Özakşit G; Güzel Aİ; Cavkaytar S; Kaba M; Topçu HO
Taiwan J Obstet Gynecol; 2015 Jun; 54(3):236-9. PubMed ID: 26166333
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
[TBL] [Abstract][Full Text] [Related]
7. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
8. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
9. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of peri- and postmenopausal ovarian cysts.
Reimer T; Gerber B; Müller H; Jeschke U; Krause A; Friese K
Maturitas; 1999 Jan; 31(2):123-32. PubMed ID: 10227005
[TBL] [Abstract][Full Text] [Related]
11. Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma.
Menon U; Riley SC; Thomas J; Bose C; Dawnay A; Evans LW; Groome NP; Jacobs IJ
BJOG; 2000 Sep; 107(9):1069-74. PubMed ID: 11002947
[TBL] [Abstract][Full Text] [Related]
12. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
Będkowska GE; Ławicki S; Gacuta E; Pawłowski P; Szmitkowski M
J Ovarian Res; 2015 May; 8():27. PubMed ID: 25935153
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
14. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses.
Tanir HM; Ozalp S; Yalcin OT; Colak O; Akcay A; Senses T
Eur J Gynaecol Oncol; 2003; 24(3-4):271-4. PubMed ID: 12807238
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
18. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
19. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.
McIntosh MW; Drescher C; Karlan B; Scholler N; Urban N; Hellstrom KE; Hellstrom I
Gynecol Oncol; 2004 Oct; 95(1):9-15. PubMed ID: 15385104
[TBL] [Abstract][Full Text] [Related]
20. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
